366 related articles for article (PubMed ID: 24916472)
1. The role of HIF1α in renal cell carcinoma tumorigenesis.
Gudas LJ; Fu L; Minton DR; Mongan NP; Nanus DM
J Mol Med (Berl); 2014 Aug; 92(8):825-36. PubMed ID: 24916472
[TBL] [Abstract][Full Text] [Related]
2. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
3. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
4. Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α.
Fu L; Wang G; Shevchuk MM; Nanus DM; Gudas LJ
Cancer Res; 2011 Nov; 71(21):6848-56. PubMed ID: 21908555
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis.
Pasupuleti V; Du W; Gupta Y; Yeh IJ; Montano M; Magi-Galuzzi C; Welford SM
J Biol Chem; 2014 Feb; 289(6):3713-23. PubMed ID: 24356968
[TBL] [Abstract][Full Text] [Related]
6. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
[TBL] [Abstract][Full Text] [Related]
7. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma.
Ruf M; Moch H; Schraml P
Int J Cancer; 2016 Jul; 139(2):396-403. PubMed ID: 26945902
[TBL] [Abstract][Full Text] [Related]
9. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
10. Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.
Szendrői A; Szász AM; Kardos M; Tőkés AM; Idan R; Szűcs M; Kulka J; Nyirády P; Szendrői M; Szállási Z; Győrffy B; Tímár J
Oncotarget; 2016 Jul; 7(27):42086-42098. PubMed ID: 27244898
[TBL] [Abstract][Full Text] [Related]
11. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
[TBL] [Abstract][Full Text] [Related]
12. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis.
Liu XD; Yao J; Tripathi DN; Ding Z; Xu Y; Sun M; Zhang J; Bai S; German P; Hoang A; Zhou L; Jonasch D; Zhang X; Conti CJ; Efstathiou E; Tannir NM; Eissa NT; Mills GB; Walker CL; Jonasch E
Oncogene; 2015 May; 34(19):2450-60. PubMed ID: 24998849
[TBL] [Abstract][Full Text] [Related]
13. Analyses of the transcriptome and metabolome demonstrate that HIF1α mediates altered tumor metabolism in clear cell renal cell carcinoma.
Minton DR; Fu L; Chen Q; Robinson BD; Gross SS; Nanus DM; Gudas LJ
PLoS One; 2015; 10(4):e0120649. PubMed ID: 25830305
[TBL] [Abstract][Full Text] [Related]
14. Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis.
Fu L; Wang G; Shevchuk MM; Nanus DM; Gudas LJ
Cancer Res; 2013 May; 73(9):2916-25. PubMed ID: 23447580
[TBL] [Abstract][Full Text] [Related]
15. CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.
Trac N; Oh HS; Jones LI; Caliliw R; Ohtake S; Shuch B; Chung EJ
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500549
[TBL] [Abstract][Full Text] [Related]
16. HIF1α is not a target of 14q deletion in clear cell renal cancer.
Shenoy N
Sci Rep; 2020 Oct; 10(1):17642. PubMed ID: 33077781
[TBL] [Abstract][Full Text] [Related]
17. HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.
Qiu B; Ackerman D; Sanchez DJ; Li B; Ochocki JD; Grazioli A; Bobrovnikova-Marjon E; Diehl JA; Keith B; Simon MC
Cancer Discov; 2015 Jun; 5(6):652-67. PubMed ID: 25829424
[TBL] [Abstract][Full Text] [Related]
18. FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.
Gstalder C; Ader I; Cuvillier O
Mol Cancer Ther; 2016 Oct; 15(10):2465-2474. PubMed ID: 27507852
[TBL] [Abstract][Full Text] [Related]
19. A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2.
Kim SY; Keillor JW
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260198
[TBL] [Abstract][Full Text] [Related]
20. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]